​

Akebia Therapeutics (AKBA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

AKBA Stock Forecast

Akebia Therapeutics (AKBA) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $6.50, with a high of $7.00 and a low of $6.00. This represents a 105.05% increase from the last price of $3.17.

$1 $2 $3 $4 $5 $6 $7 High: $7 Avg: $6.5 Low: $6 Last Closed Price: $3.17

AKBA Stock Rating

Akebia Therapeutics stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (63.64%), 3 Hold (27.27%), 1 Sell (9.09%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 1 3 7 Strong Sell Sell Hold Buy Strong Buy

AKBA Price Target Upside V Benchmarks

TypeNameUpside
StockAkebia Therapeutics105.05%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$3.17$3.17$3.17
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2523---5
Sep, 2523---5
Aug, 2523---5
Jul, 2523---5
Jun, 2513---4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 28, 2024Ed ArceH.C. Wainwright$6.00$1.98203.03%89.27%
Mar 03, 2022Serge BelangerNeedham$7.00$2.65164.15%120.82%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 11, 2024H.C. WainwrightBuyBuyhold
Sep 06, 2024H.C. WainwrightBuyBuyhold
Aug 12, 2024H.C. WainwrightBuyBuyhold
Mar 28, 2024H.C. WainwrightBuyBuyhold
May 31, 2023Seaport GlobalSector Weightdowngrade
Mar 03, 2022NeedhamBuyBuyhold
Apr 29, 2021Mizuho SecuritiesBuyBuyhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.53$-1.48$-0.58$-0.28$-0.33----
Avg Forecast$-2.54$-1.64$-0.64$-0.31$-0.31$-0.16$0.11$0.42$0.90
High Forecast$-2.15$-1.39$-0.52$-0.29$-0.26$0.09$0.44$0.44$0.97
Low Forecast$-2.94$-1.89$-0.78$-0.33$-0.35$-0.40$-0.22$0.40$0.84
Surprise %-0.39%-9.76%-9.38%-9.68%6.45%----

Revenue Forecast

$100M $190M $280M $370M $460M $550M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$295.31M$213.58M$292.60M$194.62M$160.18M----
Avg Forecast$288.48M$205.76M$284.82M$193.88M$151.04M$180.19M$245.43M$349.12M$483.65M
High Forecast$323.29M$230.59M$332.62M$194.55M$155.07M$185.14M$259.86M$369.65M$512.09M
Low Forecast$254.56M$181.56M$243.22M$193.21M$147.00M$175.24M$233.27M$331.83M$459.69M
Surprise %2.37%3.80%2.73%0.38%6.05%----

Net Income Forecast

$-400M $-280M $-160M $-40M $80M $200M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-349.87M$-244.87M$-106.01M$-51.92M$-69.41M----
Avg Forecast$-262.59M$-306.82M$-91.30M$-51.92M$-57.28M$-38.54M$24.86M$78.74M$168.72M
High Forecast$-210.08M$-259.92M$-44.14M$-25.10M$-49.64M$17.22M$82.48M$82.31M$181.62M
Low Forecast$-315.11M$-354.96M$-138.46M$-78.75M$-64.91M$-75.35M$-41.24M$75.16M$157.85M
Surprise %33.23%-20.19%16.11%-21.18%----

AKBA Forecast FAQ

Is Akebia Therapeutics stock a buy?

Akebia Therapeutics stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 3 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Akebia Therapeutics is a favorable investment for most analysts.

What is Akebia Therapeutics's price target?

Akebia Therapeutics's price target, set by 11 Wall Street analysts, averages $6.5 over the next 12 months. The price target range spans from $6 at the low end to $7 at the high end, suggesting a potential 105.05% change from the previous closing price of $3.17.

How does Akebia Therapeutics stock forecast compare to its benchmarks?

Akebia Therapeutics's stock forecast shows a 105.05% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Akebia Therapeutics over the past three months?

  • October 2025: 40.00% Strong Buy, 60.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 40.00% Strong Buy, 60.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 40.00% Strong Buy, 60.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Akebia Therapeutics’s EPS forecast?

Akebia Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.16, marking a -51.52% decrease from the reported $-0.33 in 2024. Estimates for the following years are $0.11 in 2026, $0.42 in 2027, and $0.9 in 2028.

What is Akebia Therapeutics’s revenue forecast?

Akebia Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $180.19M, reflecting a 12.49% increase from the reported $160.18M in 2024. The forecast for 2026 is $245.43M, followed by $349.12M for 2027, and $483.65M for 2028.

What is Akebia Therapeutics’s net income forecast?

Akebia Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-38.544M, representing a -44.47% decrease from the reported $-69.41M in 2024. Projections indicate $24.86M in 2026, $78.74M in 2027, and $168.72M in 2028.